» Articles » PMID: 11466340

CD4+CD25high Regulatory Cells in Human Peripheral Blood

Overview
Journal J Immunol
Date 2001 Jul 24
PMID 11466340
Citations 610
Authors
Affiliations
Soon will be listed here.
Abstract

Thymectomy in mice on neonatal day 3 leads to the development of multiorgan autoimmune disease due to loss of a CD(+)CD25(+) T cell regulatory population in their peripheral lymphoid tissues. Here, we report the identification of a CD4(+) population of regulatory T cells in the circulation of humans expressing high levels of CD25 that exhibit in vitro characteristics identical with those of the CD4(+)CD25(+) regulatory cells isolated in mice. With TCR cross-linking, CD4(+)CD25(high) cells did not proliferate but instead totally inhibited proliferation and cytokine secretion by activated CD4(+)CD25(-) responder T cells in a contact-dependent manner. The CD4(+)CD25(high) regulatory T cells expressed high levels of CD45RO but not CD45RA, akin to the expression of CD45RB(low) on murine CD4(+)CD25(+) regulatory cells. Increasing the strength of signal by providing either costimulation with CD28 cross-linking or the addition of IL-2 to a maximal anti-CD3 stimulus resulted in a modest induction of proliferation and the loss of observable suppression in cocultures of CD4(+)CD25(high) regulatory cells and CD4(+)CD25(-) responder cells. Whereas higher ratios of CD4(+)CD25(high) T cells are required to suppress proliferation if the PD-L1 receptor is blocked, regulatory cell function is shown to persist in the absence of the PD-1/PD-L1 or CTLA-4/B7 pathway. Thus, regulatory CD4 T cells expressing high levels of the IL-2 receptor are present in humans, providing the opportunity to determine whether alterations of these populations of T cells are involved in the induction of human autoimmune disorders.

Citing Articles

T Cell Development: From T-Lineage Specification to Intrathymic Maturation.

Golzari-Sorkheh M, Yoganathan K, Chen E, Singh J, Zuniga-Pflucker J Adv Exp Med Biol. 2025; 1471:81-137.

PMID: 40067585 DOI: 10.1007/978-3-031-77921-3_4.


Early Systemic Immune Response to Silicone Breast Implants Analyzed by Flow Cytometry.

Papanikolaou G, Varvarousis D, Markopoulos G, Bouranta K, Dimitriadis S, Kitsouli A Cureus. 2025; 17(2):e78500.

PMID: 40051927 PMC: 11884710. DOI: 10.7759/cureus.78500.


T-regulatory cells for the treatment of autoimmune diseases.

Fisher M, Sennikov S Front Immunol. 2025; 16:1511671.

PMID: 39967659 PMC: 11832489. DOI: 10.3389/fimmu.2025.1511671.


Changes in CD4+CD25HIGH T cells and TGFβ1 levels in different stages of adult-onset type 1 diabetes.

Milicic T, Jotic A, Markovic I, Popadic D, Lalic K, Uskokovic V J Med Biochem. 2025; 43(6):915-926.

PMID: 39876913 PMC: 11771973. DOI: 10.5937/jomb0-49868.


Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies.

Zhang Y, Wei R, Song G, Yang X, Zhang M, Liu W MAbs. 2024; 16(1):2419838.

PMID: 39497266 PMC: 11540081. DOI: 10.1080/19420862.2024.2419838.